DEFINITIONS
Overweight and obese states may result from a variety of factors [8] , including an imbalance between calories consumed and expended that leads to fat accumulation, and may impair health. Body mass index (BMI) is a simple measure to classify body size in adults. Body mass index is defined as a person's weight in kilograms divided by the square of their height in meters (kg/m 2 ). The World Health Organization defines obesity as a BMI ≥30 kg/ m 2 [9] . Although BMI typically correlates with total percentage of body fat, in persons with low muscle mass, a normal (18.5-24.9 kg/m 2 ) BMI may represent excess adiposity. For this reason, some authorities define obesity as body fat >25% for men or >33% for women [10] ; however, this requires specialized techniques for body fat measurement (such as dual-energy x-ray absorptiometry [DXA] or bioelectrical impedance analysis) that are less standardized and less readily obtainable in clinical practice.
In the setting of treated HIV, lipohypertrophy refers to localized abnormal fat accumulation, most commonly of the intra-abdominal compartment (visceral adipose tissue [VAT] ), breasts, dorso-cervical area (buffalo hump), and/or as discrete accumulations under the skin (lipomas). Lipohypertrophy can occur in >1 regions simultaneously, with or without concurrent peripheral fat loss in the limbs or face (lipoatrophy) [11] . The coexistence of lipohypertrophy and lipoatrophy is referred to as mixed lipodystrophy. The causes of lipohypertrophy are not fully understood. Confounding the matter, generalized obesity and central lipohypertrophy can overlap in an aging population with traditional and HIV-/ART-specific risk factors.
PATHOPHYSIOLOGY

Obesity
Obesity is often multifactorial [8] ; sedentary lifestyle and intake of excess or poorer quality calories (saturated fats, processed sugars) are significant risk factors [12] . Age, genetics, comorbid diseases, alcohol, certain medications, and resting metabolic rate also contribute [13] . Additionally, aging is associated with physiologic central fat redistribution, adipocyte senescence, and chronic inflammation [14] , which may be enhanced in HIV-infected individuals.
The gut microbiome may play an important role in obesity development [15] . Microbiome alterations in obesity include increased energy harvest from food [16] ; altered secretion of gut hormones that affect satiety, such as glucagon-like peptide-1 (GLP-1) [17] ; increased lipopolysaccharide shedding [18] , leading to activation of inflammatory pathways that promote ectopic fat deposition; production of byproducts that alter insulin-glucose homeostasis [19] ; and modulation of innate immunity and the autonomic nervous system [20] . Indeed, increased sympathetic (leading to leptin excess) and parasympathetic (stimulating adipogenesis) nervous system activity have been associated with obesity, particularly central adiposity [21] . Finally, activation of the renin-angiotensin system is associated with visceral adiposity and insulin resistance [22] .
Fat type and distribution also influence clinical impact: In HIV-uninfected persons, VAT and subcutaneous adipose tissue (SAT) metabolism and inflammatory signatures vary, with VAT (and particularly hepatic fat) accumulation associated with more pronounced sequelae [23] [24] [25] . In HIV-infected persons on suppressive ART, VAT and SAT metabolic and inflammatory signatures are less well understood; however, less proinflammatory signal induction in VAT may protect this depot from fat loss and promote metabolic dysfunction and systemic inflammation [26] .
Lipohypertrophy
The etiology of lipohypertrophy in treated HIV infection is multifactorial. There is likely a direct role for HIV: adipose tissue may serve as a reservoir for HIV, altering the local tissue environment and promoting enhanced adipose tissue inflammation [27] . Indeed, altered adipocyte differentiation and enhanced fat inflammation have been reported in ART-untreated HIV controllers [28] . HIV proteins (Tat, Nef, Vpr) alter adipose tissue function and increase inflammation in preclinical models [29] . Finally, the endoribonuclease DICER, which is downregulated by Vpr, is associated with lipohypertrophy and altered brown adipocyte function [30] .
HIV-associated chronic inflammation and immune activation may play a direct role in the development of lipohypertrophy, with circulating CD8 + T-lymphocyte activation linked to VAT accumulation [31] . Similar to obesity, hormonal imbalances (eg, hypogonadism, growth hormone deficiency, renin-angiotensin system activation) and gut microbiome alterations may play adjunct roles [32] [33] [34] . Antiretroviral therapy's role in lipohypertrophy and VAT accumulation is evolving. Although lipoatrophy in HIVinfected persons is mainly linked to the use of thymidine analog nucleoside reverse-transcriptase inhibitors (NRTIs) [35, 36] , in the modern ART era patients are more likely to experience fat increases [37] [38] [39] , and the role of ART in fat gain remains uncertain [40, 41] . In vitro, ritonavir-boosted protease inhibitors (PIs) induce cellular senescence, oxidative stress and inflammation, and accumulation of the senescence protein prelamin-A in adipose tissue [42] , as observed in buffalo hump fat with a brown fat-like phenotype [43, 44] . Additionally, multiple ART classes (including PIs, NRTIs, and non-NRTIs [NNRTIs]) have been associated with impaired adipogenesis, adipocyte differentiation, or function [45, 46] . Impairment of lipid and/or glucose metabolism by these agents further stimulates a proinflammatory environment detrimental to adipose tissue.
Clinical trials have assessed the role of ART in the development of lipohypertrophy. Overall, no differential effect of the NRTI or NNRTI classes has been observed. The integrase strand transfer inhibitor (INSTI) raltegravir led to similar VAT accumulation when compared with PIs [38] , but the effects of other INSTIs remain uncertain. The role of PIs also remains uncertain. Although PIs do not generally lead to more lipohypertrophy than NNRTIs [47] , ritonavir-boosted atazanavir may be an exception: when this specific PI was compared with NNRTIs and older PIs, there was a trend toward greater gains in central fat [48, 49] . However, ritonavir-boosted atazanavir and darunavir performed similarly in 2 other studies [38, 50] .
CONSEQUENCES OF OBESITY AND LIPOHYPERTROPHY
Obesity likely has similar metabolic and inflammatory consequences in HIV-infected persons as in the general population ( Figure 1 ). Obesity and lipohypertrophy, particularly VAT accumulation, are often associated with chronic inflammation in adipose tissue, insulin resistance [51] [52] [53] [54] , increased metabolic syndrome risk [55] , dyslipidemia [56] and increased oxidative stress [57] ; abdominal obesity is robustly associated with cardiovascular disease (CVD) risk and mortality [58] [59] [60] . However, for any given BMI, HIV infection appears to confer greater Poorer neurocognitive function was associated with increased waist circumference (WC) among HIV-infected participants in the CHARTER study [25] . Similarly, in the Multicenter AIDS Cohort Study, VAT was strongly associated with regional brain atrophy (which precedes neurocognitive decline), irrespective of HIV serostatus [S70] .
Multimorbidity is the accumulation of multiple, serious chronic health conditions. In some cases, these conditions may interact to amplify morbidity and mortality [S71]. For example, obesity is directly associated with detrimental effects on muscle Finally, in addition to metabolic and inflammatory consequences, body fat changes are stigmatizing and may impact self-esteem, affect ART adherence, lead to depression, and decrease quality of life [S75] . . Secondary causes of new onset or worsening weight gain should be considered when relevant, including Cushing's syndrome caused by corticosteroids coadministered with PIs or cobicistat [S99, S100]. In keeping with the screening recommendations above, we strongly recommend blood pressure and glycemic control, smoking cessation, and aspirin and/or statin use in all patients with appropriate risk profiles.
MANAGEMENT OF OBESITY AND LIPOHYPERTROPHY
Lifestyle Changes
Structured exercise with or without dietary intervention reduces abdominal obesity in most studies of HIV-infected persons [S101-S108]. Although no studies directly compare dietary and/or exercise interventions, studies with a dietary component have generally been effective in reducing weight and WC but have not consistently resulted in improved glucose metabolism [S101, S102, S109]. A higher fiber diet has been associated with reduced obesity [S110] but not VAT [S111]. Disproportionate SAT loss with diet or exercise has not been observed, providing reassurance that neither worsens preexisting lipoatrophy. One study found no benefit in adding exercise to a low-fat diet [S104]. Data on the efficacy of resistance versus aerobic training are lacking in this population.
In summary, data are insufficient to support any specific dietary or exercise strategy in patients with HIV and abdominal obesity. Although long-term lifestyle intervention adherence may be low, in persons with generalized or abdominal obesity we recommend ≥30 minutes of moderate-intensity physical activity most days of the week plus caloric restriction to ≥500 kcal/d below usual intake (guided by a nutrition professional) to attain and sustain 5%-10% weight loss [S112]. As in the general population, adjuvant behavioral therapy may by helpful in achieving sustained lifestyle modifications.
Role of ART
As above, initiation of NNRTI-, PI-, and INSTI-based ART is generally associated with SAT and VAT gain, although data are lacking with the newer INSTIs (elvitegravir and dolutegravir). Similarly, randomized switch studies have not shown a benefit of switching from a PI ( Table 1 ).
Medical Interventions
Obesity
For patients without isolated central lipohypertrophy but BMI ≥27 kg/m 2 with comorbidity or BMI >30 kg/m 2 without comorbidity, pharmacologic treatment can be considered in addition to diet, exercise, and behavioral modification. There are 5 medications or medication combinations currently approved in the United States to treat obesity in the general population (Table 2) , all of which can lead to clinically significant weight loss (≥5% over 1 year) [S113]. Because not all patients will respond, discontinuation or switch to another agent is recommended after 3 months if ≥5% weight loss has not been achieved [S114] . No agent has emerged as first-line therapy. Choice of medication depends on cost, availability, comorbidities, concomitant medications, and side effects. In the general population, phentermine/topiramate and liraglutide demonstrate the highest probability of achieving significant weight loss, whereas naltrexone/bupropion and liraglutide are associated with the highest rates of discontinuation due to an adverse event [S113]. Potential drug-drug interactions between antiobesity medication and ART are shown in Table 2 .
In patients with DM, medications also associated with weight loss, including GLP-1 receptor agonists, should be considered. In patients with CVD or uncontrolled hypertension, sympathomimetics such as phentermine should be avoided [S114].
Lipohypertrophy
Growth Hormone Axis Therapy. Given growth hormone's (GH's) lipolytic effects and the association between reduced GH and increased VAT [32, S115, S116], GH axis therapies have specifically been studied for VAT accumulation in HIV.
Recombinant human GH (rhGH) at supraphysiologic doses (1-6 mg daily) significantly decreases VAT, with some SAT reduction [S117-S121]. However, most studies demonstrate deleterious effects of rhGH on glucose homeostasis. Indeed, rhGH decreases glucose tolerance even at physiologic levels [S122]. Thus, rhGH was not approved by the US Food and Drug Administration for use in HIV-associated lipodystrophy [S123].
Tesamorelin, a GH-releasing hormone analog, is the only drug approved (in some countries) to reduce excess VAT in treated HIV infection. Tesamorelin increases endogenous pituitary GH release, reducing VAT by approximately 15% within 6 months among HIV-infected patients with baseline WC ≥95 cm for males or ≥94 cm for females [S124-S127]. Approximately twothirds of patients respond to treatment without decreases in SAT [S127]. Increased fasting glucose may occur in a minority of patients and tends to be transient [S127-S129]. Tesamorelin is administered at a fixed dose of 2 mg subcutaneously daily. It has no known significant interactions with ART.
A limitation of tesamorelin is that VAT quantity returns to baseline, on average, by 6 months after discontinuation [S127]. Measuring WC as a VAT surrogate is recommended after 6 months of treatment, along with assessment of quality of life and lipid levels. Any reduction in WC may represent a meaningful reduction in VAT and should also be interpreted in the context of other factors, including patient well-being, quality of abdominal fat on exam, and change in glucose and lipid parameters. Treatment discontinuation should be considered in patients not achieving WC reduction by 6 months. Tesamorelin should be stopped if significant increases in fasting glucose or HbA1C develop. Although tesamorelin did not worsen glucose in diet-controlled diabetics [S124], it should be used cautiously in patients with diabetes, particularly those with suboptimal glycemic control. Tesamorelin is contraindicated in patients with active malignancy and those who are pregnant or trying to achieve pregnancy. Insulin-like growth factor 1 (IGF-1) levels should be monitored 6 months after initiation, with reduction or discontinuation if IGF-1 levels exceed the upper limit of normal. Injection site reactions require discontinuation in 2%-3% of patients [S124]. [S130-S136], and some studies show lipid [S131, S136-S138] and blood pressure benefits [S134]. Metformin is associated with small decreases in BMI (typically ≤1 kg/m 2 ) [S131, S134, S135, S137], with proportional reductions in VAT in some, but not all, studies [S133, S134, S136-S139]. Metformin also improves markers of fibrinolysis [S135, S140] and endothelial function [S138] and decreases progression of coronary artery calcium [S130]. Thus, in patients with lipohypertrophy, particularly those with impaired glycemia, we recommend (off-label) consideration of metformin for its potential metabolic and cardiovascular benefits rather than specific (and potentially modest) effects on BMI or VAT. Of note, concomitant dolutegravir administration increases metformin concentrations such that 1000 mg daily of metformin is the maximum recommended dose [S141, S142].
Metformin. Metformin improves insulin resistance in HIV-infected individuals with underlying metabolic disease
Other Agents. The thiazolidinediones (TZDs) rosiglitazone and pioglitazone improve insulin sensitivity [S133, S138, S143-S146] with no effect or an increase in SAT or VAT [S133, S138, S143-S145, S147]. Thus, we do not recommend TZDs for the treatment of lipohypertrophy. Recombinant human leptin (metreleptin) provides metabolic benefit and VAT reduction in HIVinfected persons with severe lipoatrophy and decreased leptin levels in small studies [S148-S150] but is neither indicated nor approved by the US Food and Drug Administration for the treatment of HIV-associated lipohypertrophy. Physiologic testosterone replacement may be considered for patients with hypogonadism assessed by measuring morning free testosterone with a reliable assay [S151] and may decrease overall fat mass [S152]. However, testosterone has not been shown to decrease VAT in HIV [S152], and lipohypertrophy per se is not an indication for testosterone supplementation in HIV-infected adults.
Surgical Interventions
Obesity
Weight-loss (bariatric) surgery is the most effective treatment for obesity, resulting in an average 60%-70% loss of excess body weight and marked improvements in obesity-related conditions [S153-S155]. There are limited data regarding safety and efficacy in HIV, but in small case series, both Roux-en-Y gastric bypass and vertical sleeve gastrectomy appear to be safe, without changes in virologic control or ART drug concentrations [S156-S160]. However, transient but reversible reductions in tenofovir disoproxil fumarate concentrations were recently reported following vertical sleeve gastrectomy without CD4 + T lymphocyte count or HIV-1 RNA alterations [S161], and a more definitive study of ART pharmacokinetics after bariatric surgery is needed. Bariatric surgery should be considered in persons with a BMI ≥40 kg/m 2 or a BMI ≥35 kg/m 2 with obesity-related comorbidities that are refractory to serious attempts at lifestyle changes.
Lipohypertrophy
HIV-infected individuals with dorsocervical or anterior cervical fat accumulation and pain and/or functional limitations may be candidates for surgical intervention, including suction-assisted lipectomy and dermolipectomy. Fat accumulation may recur, however, requiring repeat procedures. Large studies are lacking, with case studies reporting recurrence rates from 0%-50% [S162-S166]. Data on the metabolic effects of surgical fat removal are also lacking. To our knowledge, there are no reports of surgical omentectomy in HIV-infected patients. Abbreviations: ART, antiretroviral therapy; ATV/r, ritonavir-boosted atazanavir; BID, twice daily; CYP2B6, cytochrome P450 2B6; CYP3A4, cytochrome P450 3A4; EFV, efavirenz; GABA, gamma-aminobutyric acid; GLP-1, glucagon-like peptide-1; MAOI, monoamine oxidase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; QD, once daily; RTV, ritonavir; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TID, three times daily. a Please see prescribing information for specific details including starting dose and dose titration.
CONCLUSIONS
Obesity and lipohypertrophy are common disease states in treated HIV infection that may have overlapping pathophysiologies and/or synergistic metabolic consequences. Prevention and treatment of these disease states are critical to the present and future health of HIV-infected persons. Although promising treatment strategies exist, further research is needed to better understand the pathophysiology and optimal treatment of obesity and lipohypertrophy in the modern ART era.
